JAK/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease

Pawankar, 2013, World Allergy Organization (WAO) white book on allergy, Update Zuberbier, 2014, Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review, Allergy, 69, 1275, 10.1111/all.12470 Zheng, 2011, The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma, Allergy Asthma Immunol Res, 3, 67, 10.4168/aair.2011.3.2.67 Lio, 2014, Clinical management of atopic dermatitis: practical highlights and updates from the atopic dermatitis practice parameter 2012, J Allergy Clin Immunol Pract, 2, 361, 10.1016/j.jaip.2014.02.015 Muraro, 2016, Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis—PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology, J Allergy Clin Immunol, 137, 1347, 10.1016/j.jaci.2016.03.010 Regan, 2017, Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity, J Allergy Clin Immunol, 140, 875, 10.1016/j.jaci.2017.03.013 Duan, 2005, An anti–inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model, Int Immunopharmacol, 5, 495, 10.1016/j.intimp.2004.10.015 Huang, 2017, Comprehensive attenuation of IL-25-induced airway hyperresponsiveness, inflammation and remodelling by the PI3K inhibitor LY294002, Respirology, 22, 78, 10.1111/resp.12880 Cahill, 2017, KIT inhibition by imatinib in patients with severe refractory asthma, N Engl J Med, 376, 1911, 10.1056/NEJMoa1613125 Villarino, 2017, Mechanisms and consequences of Jak-STAT signaling in the immune system, Nat Immunol, 18, 374, 10.1038/ni.3691 Stark, 2018, Responses to cytokines and interferons that depend upon JAKs and STATs, Cold Spring Harb Perspect Biol, 10, 10.1101/cshperspect.a028555 Macchi, 1995, Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID), Nature, 377, 65, 10.1038/377065a0 Russell, 1995, Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development, Science, 270, 797, 10.1126/science.270.5237.797 Holland, 2007, STAT3 mutations in the Hyper-IgE syndrome, N Engl J Med, 357, 1608, 10.1056/NEJMoa073687 Hsieh, 2011, JAK-1 rs2780895 C-related genotype and allele but not JAK-1 rs10789166, rs4916008, rs2780885, rs17127114, and rs3806277 are associated with higher susceptibility to asthma, Genet Test Mol Biomarkers, 15, 841, 10.1089/gtmb.2011.0002 Jiang, 2017, Association analyses identify two susceptibility loci 5q31 and 5q22.1 for atopic dermatitis in Chinese Han population, Asian Pac J Allergy Immunol, 35, 196 Shen, 2016, Association between JAK1 gene polymorphisms and susceptibility to allergic rhinitis, Asian Pac J Allergy Immunol, 34, 124 Gandhi, 2016, Targeting key proximal drivers of type 2 inflammation in disease, Nat Rev Drug Discov, 15, 35, 10.1038/nrd4624 Rochman, 2010, Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling, Proc Natl Acad Sci USA, 107, 19455, 10.1073/pnas.1008271107 Levy, 2015, Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate, J Am Acad Dermatol, 73, 395, 10.1016/j.jaad.2015.06.045 Busse, 2013, Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients, J Allergy Clin Immunol, 131, 339, 10.1016/j.jaci.2012.10.013 Barnes, 2012, A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma, Clin Exp Allergy, 42, 38, 10.1111/j.1365-2222.2011.03813.x Singh, 2013, Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459, Eur Respir J, 41, 46, 10.1183/09031936.00092111 Horak, 2012, The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial, Allergy, 67, 1572 Miller, 2017, A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma, Allergy Asthma Proc, 38, 157, 10.2500/aap.2017.38.4034 Hall, 2015, Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment, Pulm Pharmacol Ther, 32, 37, 10.1016/j.pupt.2015.03.003 Krug, 2014, Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis, J Allergy Clin Immunol, 133, 414, 10.1016/j.jaci.2013.10.013 Erpenbeck, 2016, The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma, Pulm Pharmacol Ther, 39, 54, 10.1016/j.pupt.2016.06.005 Gonem, 2016, Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial, Lancet Respir Med, 4, 699, 10.1016/S2213-2600(16)30179-5 Bateman, 2017, Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids, Eur Respir J, 50, 10.1183/13993003.00670-2017 Kuna, 2016, Two phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma, Drug Des Devel Ther, 10, 2759, 10.2147/DDDT.S105142 Ratner, 2017, Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from phase 2 and phase 3 randomized, double-blind, placebo- and active-referenced studies, Allergy Asthma Clin Immunol, 13, 18, 10.1186/s13223-017-0183-z Samrao, 2012, A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults, Arch Dermatol, 148, 890, 10.1001/archdermatol.2012.812 Volf, 2012, A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis, J Drugs Dermatol, 11, 341 Singh, 2010, The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma, Respir Res, 11, 26, 10.1186/1465-9921-11-26 van Schalkwyk, 2005, Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions, J Allergy Clin Immunol, 116, 292, 10.1016/j.jaci.2005.04.023 Gauvreau, 2011, Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects, Respir Res, 12, 140, 10.1186/1465-9921-12-140 Louw, 2007, Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge, Respiration, 74, 411, 10.1159/000095677 Bateman, 2006, Efficacy and safety of roflumilast in the treatment of asthma, Ann Allergy Asthma Immunol, 96, 679, 10.1016/S1081-1206(10)61065-4 Bousquet, 2006, Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma, Allergy, 61, 72, 10.1111/j.1398-9995.2005.00931.x Schmidt, 2001, The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis, J Allergy Clin Immunol, 108, 530, 10.1067/mai.2001.118596 Kostenis, 2006, Emerging roles of DP and CRTH2 in allergic inflammation, Trends Mol Med, 12, 148, 10.1016/j.molmed.2006.02.005 Lipworth, 2005, Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease, Lancet, 365, 167, 10.1016/S0140-6736(05)17708-3 Jin, 2012, Phosphodiesterase 4 and its inhibitors in inflammatory diseases, Chang Gung Med J, 35, 197 Essayan, 1999, Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation, Biochem Pharmacol, 57, 965, 10.1016/S0006-2952(98)00331-1 Pieretti, 2006, Local anti-inflammatory effect and behavioral studies on new PDE4 inhibitors, Life Sci, 79, 791, 10.1016/j.lfs.2006.02.026 Hidi, 2000, Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis, Eur Respir J, 15, 342, 10.1034/j.1399-3003.2000.15b21.x Giembycz, 1996, Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2, Br J Pharmacol, 118, 1945, 10.1111/j.1476-5381.1996.tb15629.x Hanifin, 2007, A population-based survey of eczema prevalence in the United States, Dermatitis, 18, 82, 10.2310/6620.2007.06034 Silverberg, 2014, Associations of childhood eczema severity: a US population-based study, Dermatitis, 25, 107, 10.1097/DER.0000000000000034 Spergel, 2010, From atopic dermatitis to asthma: the atopic march, Ann Allergy Asthma Immunol, 105, 99, 10.1016/j.anai.2009.10.002 Kulig, 1999, Natural course of sensitization to food and inhalant allergens during the first 6 years of life, J Allergy Clin Immunol, 103, 1173, 10.1016/S0091-6749(99)70195-8 Gustafsson, 2000, Development of allergies and asthma in infants and young children with atopic dermatitis: a prospective follow-up to 7 years of age, Allergy, 55, 240, 10.1034/j.1398-9995.2000.00391.x Silverberg, 2013, Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study, J Allergy Clin Immunol, 132, 1132, 10.1016/j.jaci.2013.08.031 Sehra, 2010, IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation, J Immunol, 184, 3186, 10.4049/jimmunol.0901860 Albanesi, 2007, IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3, J Immunol, 179, 984, 10.4049/jimmunol.179.2.984 Ong, 2002, Endogenous antimicrobial peptides and skin infections in atopic dermatitis, N Engl J Med, 347, 1151, 10.1056/NEJMoa021481 Howell, 2006, Cathelicidin deficiency predisposes to eczema herpeticum, J Allergy Clin Immunol, 117, 836, 10.1016/j.jaci.2005.12.1345 Brauweiler, 2014, Th2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6), J Invest Dermatol, 134, 2114, 10.1038/jid.2014.43 Simon, 2004, Eosinophils and atopic dermatitis, Allergy, 59, 561, 10.1111/j.1398-9995.2004.00476.x Molfino, 2012, Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor, Clin Exp Allergy, 42, 712, 10.1111/j.1365-2222.2011.03854.x Dillon, 2004, Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice, Nat Immunol, 5, 752, 10.1038/ni1084 Niyonsaba, 2010, Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells, J Immunol, 184, 3526, 10.4049/jimmunol.0900712 Comeau, 2010, The influence of TSLP on the allergic response, Mucosal Immunol, 3, 138, 10.1038/mi.2009.134 Wilson, 2013, The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch, Cell, 155, 285, 10.1016/j.cell.2013.08.057 Boniface, 2005, IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes, J Immunol, 174, 3695, 10.4049/jimmunol.174.6.3695 Wolk, 2010, Biology of interleukin-22, Semin Immunopathol, 32, 17, 10.1007/s00281-009-0188-x AbbVie, 2017 Jessup, 2008, Intradermal administration of thymic stromal lymphopoietin induces a T cell- and eosinophil-dependent systemic Th2 inflammatory response, J Immunol, 181, 4311, 10.4049/jimmunol.181.6.4311 Chevalier, 2005, Cutting edge: chemoattractant receptor-homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and eosinophil recruitment, J Immunol, 175, 2056, 10.4049/jimmunol.175.4.2056 Boehme, 2009, Antagonism of CRTH2 ameliorates chronic epicutaneous sensitization-induced inflammation by multiple mechanisms, Int Immunol, 21, 1, 10.1093/intimm/dxn118 Hijnen, 2005, Differential expression of genes involved in skin homing, proliferation, and apoptosis in CD4+ T cells of patients with atopic dermatitis, J Invest Dermatol, 125, 1149, 10.1111/j.0022-202X.2005.23932.x Iwasaki, 2002, Association of a new-type prostaglandin D2 receptor CRTH2 with circulating T helper 2 cells in patients with atopic dermatitis, J Invest Dermatol, 119, 609, 10.1046/j.1523-1747.2002.01862.x Hanifin, 1995, Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis, J Invest Dermatol, 105, 84S, 10.1038/jid.1995.17 Gantner, 1997, Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study, J Allergy Clin Immunol, 100, 527, 10.1016/S0091-6749(97)70146-5 Paller, 2016, Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults, J Am Acad Dermatol, 75, 494, 10.1016/j.jaad.2016.05.046 World Health Organization, 2007 Eriksson, 2015, Aspirin-intolerant asthma in the population: prevalence and important determinants, Clin Exp Allergy, 45, 211, 10.1111/cea.12359 Gilmour, 2006, How exposure to environmental tobacco smoke, outdoor air pollutants, and increased pollen burdens influences the incidence of asthma, Environ Health Perspect, 114, 627, 10.1289/ehp.8380 Corren, 2013, Asthma phenotypes and endotypes: an evolving paradigm for classification, Discov Med, 15, 243 Ray, 2016, Current concepts of severe asthma, J Clin Invest, 126, 2394, 10.1172/JCI84144 Elias, 2003, New insights into the pathogenesis of asthma, J Clin Invest, 111, 291, 10.1172/JCI17748 Fahy, 2015, Type 2 inflammation in asthma: present in most, absent in many, Nat Rev Immunol, 15, 57, 10.1038/nri3786 Raundhal, 2015, High IFN-gamma and low SLPI mark severe asthma in mice and humans, J Clin Invest, 125, 3037, 10.1172/JCI80911 Vanaudenaerde, 2011, Innate and adaptive interleukin-17-producing lymphocytes in chronic inflammatory lung disorders, Am J Respir Crit Care Med, 183, 977, 10.1164/rccm.201007-1196PP O'Shea, 2012, JAK and STAT signaling molecules in immunoregulation and immune-mediated disease, Immunity, 36, 542, 10.1016/j.immuni.2012.03.014 Kudlacz, 2008, The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia, Eur J Pharmacol, 582, 154, 10.1016/j.ejphar.2007.12.024 Aguilar-Pimentel, 2017, Improved efficacy of allergen-specific immunotherapy by JAK inhibition in a murine model of allergic asthma, PLoS ONE, 12, 10.1371/journal.pone.0178563 Southworth, 2016, Anti-inflammatory potential of PI3Kdelta and JAK inhibitors in asthma patients, Respir Res, 17, 124, 10.1186/s12931-016-0436-2 Pettipher, 2014, Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459, Allergy, 69, 1223, 10.1111/all.12451 Diamant, 2014, Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics, Clin Exp Allergy, 44, 1044, 10.1111/cea.12357 Spina, 2003, Theophylline and PDE4 inhibitors in asthma, Curr Opin Pulm Med, 9, 57, 10.1097/00063198-200301000-00010 Boswell-Smith, 2006, Are phosphodiesterase 4 inhibitors just more theophylline?, J Allergy Clin Immunol, 117, 1237, 10.1016/j.jaci.2006.02.045 Beghe, 2013, Phosphodiesterase-4 inhibitor therapy for lung diseases, Am J Respir Crit Care Med, 188, 271, 10.1164/rccm.201301-0021PP Adamia, 2014, PO-0990 prevalence of allergic rhinitis in children's population—Adjara region, Arch Dis Child, 99, A574 Chiang, 2012, Allergic rhinitis and non-allergic rhinitis in children in the tropics: prevalence and risk associations, Pediatr Pulmonol, 47, 1026, 10.1002/ppul.22554 Law, 2003, Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey, J Allergy Clin Immunol, 111, 296, 10.1067/mai.2003.68 Sullivan, 2001, Health economics of asthma and rhinitis. II. Assessing the value of interventions, J Allergy Clin Immunol, 107, 203, 10.1067/mai.2001.112851 Holgate, 2003, New targets for allergic rhinitis—a disease of civilization, Nat Rev Drug Discov, 2, 902, 10.1038/nrd1224 Seidman, 2015, Clinical practice guideline: allergic rhinitis, Otolaryngol Head Neck Surg, 152, S1, 10.1177/0194599814561600 Durham, 2016, Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: pooled analyses, J Allergy Clin Immunol, 138, 1081, 10.1016/j.jaci.2016.04.061 Bernstein, 2016, Allergic rhinitis: mechanisms and treatment, Immunol Allergy Clin North Am, 36, 261, 10.1016/j.iac.2015.12.004 Hunter, 2009, (Oxagen) Use of CRTH2 antagonist compounds, PCT Int Appl Willard, 2014, Characterization of QAW039 and QAV680, two novel, potent and selective CRTh2 antagonists, Eur Respir J, 44, P4072